Exogenous excitatory amino acid (EAA) agonists (glutamate or aspartate) have convulsant action when administered focally into cortical or subcortical structures [ 13. Likewise, more potent agonists acting selectively at the N-methyl-1)-aspartate (NMDA) or at the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate (KA) receptors have both excitotoxic and proconvulsant/ convulsant activity when administered systemically to rodents or primates (see . Recently, a selective agonist acting at the metabotropic receptor, 1 -amino-cyclopentane-trans-1,3-dicarboxyIic acid (t-ACPD) has also been shown to induce convulsions in rats when administered focally in the hippocampus (see Schoepp, this colloquium). Conversely, antagonists acting at both NMDA receptors (competitive antagonists, non-competitive channelsite antagonists, non-competitive glycine site antagonists) and at non-NMDA (AMPA/KA) receptors have consistently exhibited anticonvulsant activity in a wide range of experimental seizure models (see [4] ). Potent, selective antagonists for the metabotropic glutamate receptor are still lacking. Convulsions induced by t-ACPD can, however, be blocked by I .-2-amino-3 -phosphonopropionic acid (AP 3), Abbreviations used: t-ACPD, l-amino-cyclopentanetrans-1.3-dicarboxylic acid; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; U( -)CPPene, I ) ( -)(E)-4(3 -phosphonoprop -2enyl)piperazine -2 -carboxylic acid; EAA, excitatory amino acid; EEG, electroencephalography; GYKI 52466, 1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine; KA, kainate; NBQX, 2,3-dihydroxy-h-nitro-7-sulphamoylbenzo(F)-quinoxaline; NMDA, N-methyl-waspartate. known to act as an antagonist at the metabotropic receptor (see Schoepp, this colloquium).
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The proconvulsant activity of EAA agonists and anticonvulsant activity of EAA antagonists is consistent with an up-regulated E M transmitter system being one of the causative agents for enhanced seizure susceptibility in animal and human epilepsy. Numerous studies have been undertaken to establish a link between seizure susceptibility in animals or man and abnormalities in excitatory (or inhibitory) amino acid transmitter systems. On the whole, it has been difficult to correlate seizure susceptibility with any definitive alterations in endogenous, regional transmitter levels, turnover or release, or with abnormalities in regional excitatory and inhibitory receptor densities or affinities (see [ 3 , 5, 61 
Anticonvulsant properties of competitive NMDA-antagonists
Potent, selective antagonists that act competitively at the NMDA-recognition site have been available for more than 10 years, and their anticonvulsant activity has been established convincingly in a wide range of experimental seizure models (see [4] ). The anticonvulsant properties of the competitive NMDA antagonists are summarized in Table 2 .
NMDA-antagonists are effective anticonvulsants against limbic seizures (e.g. pilocarpineinduced) and against generalized clonic/tonic seizures. The antagonists are less potent against spontaneous 6-8 Hz spike-and-wave seizures in rodents, a syndrome with similar pharmacological response (inhibited by ethosuximide; not protected by phenytoin; worsened by GABAmimetic drugs), similar corticothalamic EEG-abnormalities and similar behavioural correlates to human absence seizures [27] . Amygdala-kindled seizures in rats are considered a model of partial seizures in man. Complex partial seizures represent a large portion of epilepsy cases that do not respond to clinically available antiepileptic drugs, and are therefore the initial clinical target in 'add-on' trials of novel anticonvulsant drugs. Although the epileptogenic kindling process in rats is effectively inhibited by competitive NMDA antagonists, the fully amygdalakindled seizures are relatively resistant to protection by competitive NMDA antagonists [27-321, with anticonvulsant efficacies of the antagonists being 
Anticonvulsant activity of noncompetitive NMDA antagonists
MK-801 is the most potent of the antagonists acting at the channel site of the NMDA receptor. MK-801
(0.01-0.03 mg kg-' day-') and another noncompetitive NMDA-antagonist, dextromethorphan (2 mg kg-' day-'), have been tested against partial epilepsy in man [34, 3. 51, but found to be ineffective at the doses tested. At 5-10-fold higher doses MK-801 is fully protective in a wide range of experimental seizure models. However these doses produce severe behavioural side-effects and also a marked two-threefold activation of cerebral metabolism (cerebral blood flow and glucose utilization) in limbic structures (see [4] ), making the clinical potential for this group of drugs doubtful. Recently, a structural analogue of MK-801, ( f )-5-aminocar-
, has been described [36] that has anticonvulsant activity in many seizure models and a considerably improved therapeutic index (compared with MK-80 1).
Antagonists acting at the glycine site of the NMDA receptor also have anticonvulsant activity (see [4] ). Antagonists acting selectively at this site include chlorine-and thio-derivatives of kynurenic acid. Most currently available drugs within this group have a very short time course of action and have to be administered intracerebroventricularly (i.c.v.) to exhibit anticonvulsant action. A pyrrolidone, 3-amino-1 -hydroxy-2-pyrrolidone (HA-966) has weak antagonist action at the glycine site of the NMDA receptor, whereas a methyl derivative of HA-966, L687414, is a much more potent glycine antagonist. L6874 14 protects against sound- 
Anticonvulsant properties of non-NMDA antagonists
Anticonvulsant activity has previously been associated with AMPA/KA preferring antagonists with relatively low receptor selectivity (see [4] ). The recent availability of the potent, selective antagonists for the AMPA/KA receptor, 2,3-dihydroxy-6-nitro- Recently, the nootropic drug, aniracetam (l-panisoyl-2-pyrrolidinone) has been shown to potentiate the AMPA response induced in Xenopus oocytes [42] . The enhanced response has been suggested to be due to an aniracetam-induced reduced rate of desensitization of the AMPA/KA receptor [43] . W e have recently shown that aniracetam pretreatment (12.5-100 nmol administered i.c.v. 15 min before the administration of 60 pmol/kg i.p. GYKI 52466) completely reverses the anticonvulsant protection provided by GYKI 52466 in a dose-dependent fashion (Figure 1 ). Aniracetam by itself caused no behavioural or proconvulsant action at these doses. The aniracetam-induced reversal of the anticonvulsant effect was specific for the AMPA/KA antagonists GYM 52466 and, much less potently, NBQX. The anticonvulsant activity of the competitive NMDA antagonist, U( -)CPPene, was not modified by pretreatment with 12.5-100 nmol aniracetam (A. Chapman, unpublished work).
